



IBA demonstrates leading compact Intensity Modulated Proton Therapy technologies during PTCOG52

Major advances in ProteusONE development including Pencil Beam Scanning, 3D Cone Beam Computed Tomography to be presented at PTCOG52 meeting

Louvain-la-Neuve (Belgium), May 31, 2013 — IBA (Ion Beam Applications S.A.), the global high-tech leader in next generation radiation therapy and diagnostics for the treatment of cancer, is pleased to announce that it will present major advances in **compact Intensity Modulated Proton Therapy (IMPT) technologies**, (*Proteus®ONE¹*) and Pencil Beam Scanning (PBS) during PTCOG52 in Essen, Germany (June 2-8, 2013 - Essen, Germany - Booth #A9-12).

ProteusONE is the single-room proton therapy solution developed by IBA. Its clinical capabilities will enable physicians to deliver IMPT to their patients. Pencil Beam Scanning (PBS) and 3D Cone-beam Computed Tomography (3D CBCT) make it possible to fully leverage the proton beam accuracy. With IMPT you can deliver highly conformal treatments while reducing the integral dose to healthy tissues.

Olivier Legrain, Chief Executive Officer of IBA, said: *“This year we will demonstrate our leadership at PTCOG52 by showing how IBA is making proton therapy ever more accessible to patients worldwide. IBA’s ProteusONE represents a solution that can further reduce the technological and financial risks of acquiring proton therapy technology and it is also the safest way to compact IMPT today. ProteusONE encompasses IBA’s extensive experience and world leading technology, of which the new center at WPE is the “living proof.”*”

Our clinical partners will be pleased to share with you their hands-on experience with IBA PBS during the lunch symposium organized on June 7, 2013 - 12:00 PM - 01:30 PM - PTCOG, "Europa" room.

Pencil Beam Scanning, Opening the Way to New Clinical Indication for Proton Therapy

- 1. Pencil Beam Scanning Treatment Protocols, Opening The Way To New Clinical Indication For Proton Therapy*
Dr. James M. Metz, MD, Professor and Vice Chair, Clinical Division, Radiation Oncology, University of Pennsylvania
- 2. Patient Specific Quality Assurance For Pencil Beam Scanning Treatment Plans*
Dr. Mark Pankuch, Director of Medical Physics, ProCure Proton Therapy Center – CDH
- 3. Making Proton Therapy Possible. ProteusONE: A Single-Room Solution*
Mr. Nicolas Deneff, Product Manager, IBA

¹ *ProteusONE* is the brand name of a new configuration of the Proteus 235 including some new developments subject to review by competent authorities (FDA, Notified bodies, et al.) before marketing.



This edition of PTCOG annual meeting is hosted by Westdeutsches Protonentherapiezentrum Essen (WPE). This proton therapy center is a flagship of IBA's Proteus[®] technology, which will be showcased during the Congress.

Official visit Westdeutsches Protonentherapiezentrum Essen scheduled in the program of PTCOG
June 5, 2013 - 02:00 PM - 06:00 PM (TBC)

About Proteus[®] ONE²

IBA ProteusONE is the safest way to compact Intensity Modulated Proton Therapy (IMPT). It encompasses the latest technologies of Proteus[®] PLUS, which have been developed with top clinical institutions worldwide.

ProteusONE offers IMPT powered by Pencil Beam Scanning (PBS) and 3D Cone-beam Computed Tomography (3D CBCT). It enables physicians to leverage completely on the clinical effectiveness of proton therapy. ProteusONE has been inspired by everyday clinical practice. IBA has collaborated with Philips to enhance the patient and staff experience by fostering a soothing environment making therapy safer and easier.

www.iba-proteusone.com

About Proton Therapy

Proton therapy is increasingly considered the most advanced and targeted cancer treatment due to its superior dose distribution and fewer side effects. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor and sparing healthy surrounding tissue.

IBA is the only supplier to have multiple centers treating cancer patients with Pencil Beam Scanning (PBS), the most precise form of Proton Therapy. PBS enables Intensity Modulated Proton Therapy (IMPT), allowing clinicians to precisely target a cancerous tumor by controlling both the intensity and the spatial distribution of the dose to the millimeter.

As access to proton therapy increases in Europe and across the world, IBA continues to demonstrate compassionate innovations with more patient-friendly treatment rooms and more precise therapies. IBA proton therapy systems account for more than half of the world's clinically based proton therapy facilities. To date they include 14 operational proton therapy centers worldwide, and 11 more centers in development.

About IBA

IBA (Ion Beam Applications S.A.) is the worldwide technology leader in the field of proton therapy for the diagnosis and treatment of cancer. The Company's expertise lies in the development of next generation proton therapy technologies and radiopharmaceuticals that provide oncology care providers with premium quality services and equipment, including IBA's leading fully integrated IntegraLab[®] radiopharmacy system, and Dosimetry advanced solutions for Quality Assurance of medical equipment and increased patient safety.

² ProteusONE is the brand name of a new configuration of the Proteus 235 including some new developments subject to review by competent authorities (FDA, Notified bodies, et al.) before marketing.



Headquartered in Belgium and employing more than 1,200 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

Contact

Olivier de Sadeleer

IBA

Marketing Manager, Proton Therapy

Phone : +32 10 203 342

E-mail. Olivier.deSadeleer@iba-group.com

Thomas Ralet

IBA

Vice-President Corporate Communication

+32 10 475 890

communication@iba-group.com

For media and investor enquiries:

M:Communications

Mary-Jane Elliott, Amber Bielecka, Claire Dickinson

+44 (0) 207 920 2333

IBA@mcomgroup.com